TriangleHEALTH PROFESSIONAL · SOURCE READING
Prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Inflammatory myofibroblastic tumors recur frequently but are rarely metastatic.[52-54] Studies of children with inflammatory myofibroblastic tumor show 5-year survival rates higher than 80%.[62]
Epithelioid inflammatory myofibroblastic sarcoma is an aggressive tumor that is generally treated with surgery. Before the availability of ALK inhibitors, disease progression and high mortality rates were common.[57,58,63] Epithelioid inflammatory myofibroblastic sarcoma generally responds to ALK inhibitors but progression on therapy has been observed, which is consistent with the aggressive clinical behavior of the tumor.[59]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice